Skip to main content

Padagis releases generic Doxil

Doxil liposome injection had a market value of roughly $98 million for the 12 months ended August 2021, according to IQVIA.
Sandra Levy
Levy

Padagis is offering a generic version of Doxil (doxorubicin liposome injection) through its partnership with Ayana Pharma.

The medication is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma.

[Read more: FDA OKs new indication for Roche's Tecentriq]

Doxil liposome injection had a market value of roughly $98 million for the 12 months ending August 2021, according to IQVIA.

"This launch is the culmination of several years of working with the Ayana team to bring this highly complex product to market," said Padagis executive vice president and chief growth officer Colter VanStedum. "By also highlighting our business development capabilities in leveraging our regulatory and technical expertise and commercial platform, we are able to bring this unique product to our customers and patients in need of a high-quality generic alternative."

[Read more: FDA approves Tibsova to treat bile duct cancer]

Related Topics

X
This ad will auto-close in 10 seconds